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ferences within the TBI group when serum S-100B con-
centration was taken into consideration. The fi ndings 
suggest that serum S-100B levels after mild TBI are not 
predictive of neuropsychological performance in the 
subacute stage of recovery. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 Although mild traumatic brain injury (TBI) is consid-
ered a benign neurological condition and is associated 
with uneventful recovery, many patients experience mild 
impairment of neurocognitive functioning in the ﬁ rst 
days to weeks after injury. Most experience completion 
of neuropsychological recovery in 1–3 months, although 
there is some variability in results  [1] . However, a sub-
stantial number of patients (about 10–29%) complain 
about long-term neuropsychological deﬁ cits. These pa-
tients are regarded to suffer from a persistent post-con-
cussive syndrome  [2, 3] . 
 Reported risk factors for long-term neurobehavioral 
disorders include: underdiagnosis of initial injury sever-
ity  [4] , duration of post-traumatic amnesia and uncon-
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 Abstract 
 The serum concentration of S-100B is reported to refl ect 
the severity of brain damage. The purpose of this study 
was to determine whether elevated serum S-100B con-
centrations were related to neuropsychological test per-
formance of patients in the subacute phase of recovery 
from mild traumatic brain injury (TBI). S-100B concentra-
tions were measured in blood samples taken within 6 h 
after TBI. Serum S-100B was estimated using an immu-
noluminometric assay. Cognitive speed and memory 
were assessed with neuropsychological tests at a me-
dian of 13 days (range 7–21 days) after injury. The two 
groups, formed on a median split of initial serum S-100B 
concentrations ( 1 or  ! 0.22   g/l) did not differ in age or 
education. The neuropsychological performance of the 
TBI patients was also compared with that of a healthy 
control group. Cognitive speed and memory perfor-
mance of mild TBI patients were inferior compared to 
those of healthy subjects. There were no signifi cant dif-
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sciousness  [5] , age, sex, multiple mild TBIs  [1] , chronic 
pain  [6] , comorbid depression  [7] , psychosocial stressors, 
or misattribution of everyday symptoms  [8] . In order to 
predict and prevent neuropsychological sequelae after 
mild TBI and possible development of a post-concussion-
al syndrome, there is need for an early sensitive marker 
of brain damage in patients. 
 Serum levels of protein S-100B are reported to be in-
creased after mild TBI  [9, 10] . This protein is synthesized 
in astroglial cells in all parts of CNS, so that high serum 
levels indicate damage to glial cells and blood-brain bar-
rier dysfunction. Ingebrigtsen and colleagues  [10, 11] 
showed that serum concentrations of S-100B measured 
early after head trauma provide information on diffuse 
brain damage and seem to be associated with neuropsy-
chological outcome even in mild TBI. Little is known 
about the relation between serum S-100B and neuropsy-
chological performance in the subacute stage of recovery. 
We do not know of any study relating S-100B concentra-
tions to short- and long-term neuropsychological disor-
ders in mild TBI patients only. Comparison of the predic-
tive value of neurological status and neuron-speciﬁ c eno-
lase and S-100B concentrations showed the initial protein 
S-100B concentration (median: 27 h after trauma) to be 
the best predictor of long-term neuropsychological disor-
ders in a heterogeneous cohort  [9, 10] . Patients with mild-
to-moderate TBI and neuropsychological deﬁ cits at 2 
weeks post-injury had signiﬁ cantly higher serum levels of 
S-100B release than TBI patients without neuropsycho-
logical deﬁ cits. 
 The purpose of this study was to examine whether S-
100B levels as a marker of injury severity are associated 
with neuropsychological test performance in a sample of 
patients with mild uncomplicated TBI. We hypothesized 
that subjects who had increased serum S-100B levels 
would have a poorer cognitive function than subjects who 
had a less pronounced increase in serum S-100B levels. 
 Method and Patients 
 Method 
 Patients who arrived at the emergency department within 6 h 
of a trauma and who met criteria for mild TBI were asked to give 
their informed consent for taking blood samples for S-100B mea-
surement. Blood samples were taken within 6 h after trauma and 
S-100B levels were measured using an immunoluminometric assay 
as described by de Kruijk et al.  [12] . According to the study pro-
tocol, all patients were assessed neuropsychologically between 7 
and 21 days after injury. Control subjects (n = 56) were recruited 
by means of advertisements placed in local newspapers and were 
paid for their participation. The advertisement stressed that par-
ticipants should be healthy. Control participants were screened for 
the same exclusion criteria as the mild TBI patients and underwent 
the same procedure of neuropsychological evaluation as the pa-
tient group. 
 Neuropsychological Assessment 
 The choice of the ﬁ xed neuropsychological test battery was 
based upon earlier neuropsychological studies of mild TBI patients 
by Bohnen et al.  [13] and Klein et al.  [14] . These tests have proven 
sensitivity for detecting subtle neurocognitive impairment after 
mild TBI and a variety of subclinical neurological incidents  [14–
18] . Cognitive speed was measured with two neuropsychological 
tests, the 40-item version of the Stroop test  [19] (selective attention) 
and the Letter Digit Coding test  [20] (processing speed). For data 
analysis we used the third Stroop card showing color words printed 
in ink of different colors. Memory was measured with the 15-word 
learning test, which tests immediate and delayed recall  [21] . 
 Statistical Analysis 
 Patients were divided into two groups based on a median split 
of their initial S-100B serum concentrations. We compared a group 
with low S-100B levels ( ! 0.23   g/l; n = 22) with a group with high 
S-100B levels ( 1 0.22   g/l; n = 28). The range of S-100B concentra-
tions in serum was 0.02–0.90   g/l. 
 Poor cognitive speed was deﬁ ned as a score below the 10th per-
centile on both the Stroop test and the Letter Digit Coding test. 
Poor memory was deﬁ ned as a score below the 10th percentile on 
both the immediate recall test and the delayed recall test. The neu-
ropsychological scores were converted into percentile scores by us-
ing available norms from the Maastricht Aging Study  [19] . Norma-
tive comparisons were corrected for age and education. 
 A one-way ANOVA was used to determine initial differences in 
injury characteristics and demographic variables between patient 
groups. To determine the effect of initial S-100B concentrations on 
cognitive performance, we used dichotomous endpoints, poor and 
good cognitive speed (Stroop and Letter Digit test) and poor and 
good memory (immediate and delayed recall on the word learning 
test). In these analyses we compared the cognitive function of mild 
TBI patients with high S-100B concentrations with that of patients 
with low S-100B concentrations. Odds ratios (OR) and 95% conﬁ -
dence intervals (CI) were obtained by logistic regression analysis. A 
compound cognitive score was also constructed for cognitive speed 
and memory for additional analysis. We computed two compound 
scores based on dependent variables after transformation to stan-
dard scores using normative data from the Maastricht aging study: 
cognitive speed Z(third Stroop card + Letter Digit coding)/2 and 
memory Z(immediate recall + delayed recall)/2. We compared the 
cognitive performance of the two groups of TBI patients (high ver-
sus low serum S-100B concentration) using a one-way ANOVA. 
 Patients 
 Consecutive patients (n = 50) who visited the emergency depart-
ment of the University Hospital Maastricht with an uncomplicated 
TBI were screened for inclusion in the study. Patients were includ-
ed if they met clinical criteria for mild TBI: (1) a blunt blow to the 
head resulting in post-traumatic amnesia not exceeding 1 h; (2) 
feeling dazed or initial loss of consciousness of  ! 15 min; (3) Glasgow 
Coma Scale score of 14–15 on presentation at the emergency de-
partment and (4) absence of focal neurological deﬁ cits. These cri-
teria fell within the limits proposed by the American Congress of 
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Rehabilitation Medicine  [22] . We chose to use these more conser-
vative criteria to select a homogenous sample of mild TBI patients 
who fall at the ‘mildest’ end of the TBI spectrum. 
 Patients with previous head injuries, surgical conditions, alco-
hol or substance abuse, and patients with major psychiatric, neu-
rological, medical problems or severe extracranial injuries (frac-
tures, burns) were excluded. Patients with evidence of secondary 
intracranial complications were also excluded. 
 To detect intracranial complications in the ﬁ rst 24 h following 
the injury, ‘home observation instructions’ were given to a respon-
sible person accompanying the patient. If a participant sustained 
signiﬁ cant injury in the interval between S-100B measurement and 
neuropsychological assessment, he or she was excluded from data 
analysis. Estimates of the duration of post-traumatic amnesia and 
of loss of consciousness were based on the information provided by 
patient and witnesses. 
 On average, patients (n = 37) lost consciousness for 3.2 min
(SD = 4.1; range 0–15 min) and post-traumatic amnesia (n = 50) 
lasted 18.9 min (SD = 19.0; range 1–60 min). At presentation the 
Glasgow coma scores of all patients were higher than 13. Only 4 
patients had scores of 14. There were no signiﬁ cant differences be-
tween patient groups based on high versus low serum S-100B levels 
in the duration of unconsciousness, F(1,48) = 1.215, p  ! 0.28, or 
post-traumatic amnesia, F(1,48) = 0.036, p  ! 0.90. Twenty-three 
patients (n = 50) were female (46%). 
 The average age of the total sample (n = 106) was 35.2 years 
(SD = 15.9), and the average education was 12.9 years (SD = 3.4). 
No signiﬁ cant differences were found between groups in age, 
F(2,103) = 1.043, p  ! 0.40, or years of education, F(2,103), 1.781, 
p  ! 0.20. 
 Results 
 No mild TBI patients were excluded from data analy-
sis, because of secondary intracranial complications. At 
a median of 13 days after injury (range 7–24 days) neu-
ropsychological assessment was completed. Every patient 
was neurologically examined before neuropsychological 
screening. No abnormalities that could compromise neu-
ropsychological testing were found. 
 We calculated the probability that poor cognitive func-
tion depended on the serum S-100B concentration. Ele-
vated serum S-100B level did not increase the risk of poor 
cognitive speed (OR 0.5, 95% CI 0.1–3.2) or poor mem-
ory performance (OR 1.7, 95% CI 0.3–10.1) ( tables 1,  2 ). 
Nine percent of the patients with low S-100B levels and 
14% of the patients with high S-100B levels had an im-
paired memory performance. Cognitive speed was im-
paired in 7% of the patients with high S-100B levels and 
in 14% of the patients with low S-100B levels. Parametric 
comparisons of extreme groups, based on S-100B concen-
trations, did not reveal differences in cognitive perfor-
mance (data not shown). Compound scores for cognitive 
speed and memory also did not reveal any differences in 
performance between the two TBI groups: cognitive speed 
(F(1,48) = 0.338, p  ! 0.60) and memory (F(1,48) = 0.903, 
p  ! 0.40). We found low and non-signiﬁ cant correlations 
Dependent variables Serum S-100B Control subjects
(n = 56)
<0.23 (n = 22) >0.22 (n = 28)
mean SD mean SD mean SD
Immediate recall 26.5 5.4 28.6 7.1 31.5 5.7
Delayed recall 9.4 2.9 10.3 3.6 11.0 2.6
Stroop test 42.7 12.3 38.3 7.8 38.1 11.2
Letter digit coding 33.2 7.3 34.5 7.7 38.4 6.8
See Method section for explanation of dependent variables.
Dependent variables Serum S-100B Control subjects
(n = 56)<0.23 (n = 22) >0.22 (n = 28)
Poor cognitive speed 14  7 2
Poor memory  9 14 4
See Method section for deﬁ nitions of poor cognitive speed and poor memory.
Table 1. Descriptive statistics for the three 
groups
Table 2. Percentage of subjects with
poor cognitive speed or poor memory
performance for each group
 Mild TBI, S-100B and Neurocognitive 
Performance 
 Eur Neurol 2005;53:22–26 25
between injury severity variables and S-100B concentra-
tions (r  ! 0.20, n.s.) and cognitive performance and S-
100B concentrations (r  ! 0.16, n.s.). 
 We also calculated the probability that mild TBI re-
sulted in poor cognitive function (yes/no). Memory per-
formance was impaired in 12% of mild-TBI patients but 
in only 4% of the controls (OR 3.7; 95% CI 0.7–19.2). 
Cognitive speed was impaired in 10% of mild TBI pa-
tients compared to 2% in the controls (OR 6.1; 95% CI 
0.7–54.2). 
 Discussion 
 There is still no biological marker to predict continu-
ing neuropsychological symptoms after mild TBI. Detect-
ing patients at risk of developing post-concussional symp-
toms is of potential interest, because neurobehavioral re-
habilitation can reduce the risk of persistent symptoms 
 [23] . In this study we focused on acute serum levels of 
protein S-100B as a marker for brain damage after mild 
TBI in relation to neurocognitive performance. 
 Cognitive speed and memory function were not differ-
ent in patients with or without high serum levels of pro-
tein S-100B, but were worse than those of healthy sub-
jects. These results suggest that an elevated serum S-100B 
level is not predictive of neuropsychological performance 
during recovery from mild TBI. Although neuropsycho-
logical decrements are common in this population, it is 
notable that the majority of mild TBI patients did not 
have unusually low scores on cognitive measures for 
speed and memory. 
 However, other studies with mild TBI patients have 
used different cut-off values for serum S-100B levels (0.2–
0.5   g/l)  [10, 24] and thus it is possible that higher con-
centrations of serum S-100B than those found in this 
study are associated with poorer subacute neurocognitive 
performance. 
 Blood samples were drawn within 6 h after injury. It 
is presently not known whether this is the right time frame 
to accurately measure the concentration of S-100B levels. 
There is still no consensus in the literature on the dynam-
ics of S-100B after TBI, although there is some indication 
that levels of S-100B tend to fall rapidly after release fol-
lowing severe TBI  [25] . A variety of studies using differ-
ent outcome variables have chosen different intervals be-
tween injury (or surgery) and collection of serum S-100B 
(1–48 h)  [9, 25–27] . 
 We chose 1–3 weeks after injury for neuropsychologi-
cal assessment, because it is well known that pain, anxiety 
and stress have a signiﬁ cant inﬂ uence on neuropsycho-
logical performance  [1, 2] . These are common symptoms 
following a mild TBI but tend to resolve within days after 
injury. Possible inﬂ uences of these symptoms on neuro-
cognitive performance are minimized in this way. 
 Although we used a short cognitive battery that has 
proven to be sensitive for detecting subtle neurocognitive 
impairment after mild TBI  [3] , it could be that a more 
extensive neuropsychological battery is more sensitive in 
demonstrating mild neurocognitive deﬁ cits. Herrmann et 
al.  [9] used a more extensive battery, but found mostly 
disorders of attentional performance, executive func-
tions, interference susceptibility, reduced error control, 
and memory performance. These cognitive domains are 
covered by our cognitive screening battery. 
 This study suggests that blood levels of S-100B do not 
reﬂ ect cognitive dysfunction after mild TBI. However, it 
is possible that our results would have been different if 
the blood samples had been taken at a different time. 
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